This handout is for nsaid-induced hypertensive crisis (severe htn driven by cox-1/cox-2 inhibition from indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, or celecoxib — most severe in ckd, hf, elderly, cirrhosis, or with concurrent acei/arb/diuretic via "triple whammy" mechanism causing aki; aspirin less implicated at low cardiovascular dose 81 mg/d). Your care team identified this based on: chronic or high-dose nsaid exposure (indomethacin, ketorolac, naproxen, ibuprofen, diclofenac, celecoxib) with new sbp ≥180 / dbp ≥120 — typically days-to-weeks of exposure precipitates in vulnerable patients (curhan 2002 + aw meta).
Other reasons your team may use this plan: triple whammy: nsaid + acei/arb + diuretic combination → severe htn + aki (lapi bmj 2013 pmid 23299844 — rr 1.31 for aki) — classic outpatient elderly presentation; self-medication with otc nsaid (ibuprofen, naproxen) for back pain, headache, or arthritis without prescriber awareness — common preventable cause; post-operative ketorolac for analgesia in patient with ckd or hf → severe htn + aki within 24-48 h (preventable system failure).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| nicardipine | 5 mg/h IV → titrate by 2.5 mg/h q5-15 min (max 15 mg/h) to SBP <160 within 2 h | IV | continuous infusion | AHA 2025 HTN Class I — IV nicardipine first-line for non-aortic-dissection HTN crisis; preserves cerebral perfusion + titratable; safe in volume-overloaded NSAID patients |
| furosemide | 20-40 mg IV (higher doses 80-160 mg if CKD or HF; double dose if no UOP response within 30 min) | IV | q6-12h or continuous infusion | Whelton AJM 2000 + KDIGO 2024 — overcomes renal Na+ retention from NSAID-induced prostaglandin loss; loop diuretic remains effective even in NSAID-blunted natriuresis (acts proximal to prostaglandin-dependent step); first-line for volume overload in NSAID HTN |
| labetalol | 10-20 mg IV q10 min titrate (max 300 mg cumulative), OR infusion 0.5-2 mg/min | IV | PRN bolus or continuous | Mixed α/β safe in NSAID-induced HTN; standard HTN-emergency adjunct per AHA 2025 |
| spironolactone | 25-50 mg PO daily | PO | daily | Adjunct if hypoK from loop diuretic; CONTRAINDICATED if hyperK from NSAID + ACEi triple whammy |
| potassium chloride | KCl 40 mEq PO TID OR 10-20 mEq IV/h to target K 4-5 | PO + IV | PRN | Replacement if loop diuretic dominant + hypoK; AVOID if hyperK from triple whammy |
| magnesium sulfate | 2-4 g IV | IV | PRN to target Mg 2.0-2.5 | Often coexists with hypoK; correct before K replacement effective |
| acetaminophen | 1 g PO/IV q6h (max 3-4 g/d; max 2 g/d if cirrhosis or chronic alcohol use) | PO/IV | q6h | First-line NSAID alternative for general pain; minimal cardiovascular + renal risk; max dose limit critical in liver dysfunction |
| topical diclofenac gel (1% or 2%) | 2-4 g topical q6-8h to affected area | topical | q6-8h | ACR 2020 Hochberg — topical NSAID has minimal systemic absorption; reasonable for localized MSK pain in NSAID-vulnerable patients (still some systemic exposure — use cautiously and monitor BP) |
| duloxetine | 30 mg PO daily × 1 week then 60 mg PO daily | PO | daily | ACR 2020 + AHRQ 2020 chronic pain guidelines — SNRI proven for chronic MSK pain (knee OA, low back pain, fibromyalgia); cardiovascular-neutral; reasonable NSAID alternative for chronic conditions |
| lidocaine 5% patch | 1-3 patches to affected area for up to 12h on / 12h off | topical | q12h on/off | Minimal systemic absorption; topical analgesia for localized pain; good NSAID alternative |
| gabapentin | 100-300 mg PO TID titrate (max 3600 mg/d; reduce in CKD) | PO | TID | AAN 2022 + ADA 2026 — first-line for neuropathic pain; reduce dose in CKD; cardiovascular-neutral |
| tramadol | 50-100 mg PO q4-6h (max 400 mg/d; reduce in elderly + CKD) | PO | q4-6h | Less potent opioid; safer than full opioid for moderate pain; risk of serotonin syndrome with serotonergic agents + lowers seizure threshold |
| morphine | 2-4 mg IV q3-4h or 15 mg PO q4-6h (lowest effective dose, multimodal) | IV/PO | PRN with stewardship | Reserve for severe acute pain unrelieved by alternatives; opioid stewardship critical (limit duration, lowest dose, naloxone co-prescribing for chronic users); avoid for chronic pain when possible |
| intra-articular methylprednisolone or triamcinolone | Methylprednisolone 40-80 mg or triamcinolone 20-40 mg per joint | intra-articular | q3-6 months | ACR 2020 Hochberg — minimal systemic absorption; effective for joint-specific pain; cardiovascular-neutral |
| STOP NSAID IMMEDIATELY (any route) | Discontinue all NSAID exposure | N/A | N/A | Mechanism-targeted — removing the offending agent reverses prostaglandin inhibition + RAAS upregulation; PO + IV + topical (latter has some absorption); Curhan 2002 + Aw meta — improvement within days of cessation in most patients |
| AVOID NSAIDs in CKD, HF, elderly, cirrhosis, on ACEi/ARB/diuretic (TRIPLE WHAMMY) | AVOID | N/A | N/A | Lapi BMJ 2013 PMID 23299844 — triple whammy (NSAID + ACEi + diuretic) RR 1.31 for AKI; KDIGO 2024 — NSAID-AVOID in CKD; ACC/AHA 2025 — NSAID-AVOID in HF; ACR 2020 — caution in elderly; substitute alternative pain regimen |
| NSAID-AVOID alert documented in chart + medication list | Documented as allergy/intolerance with rationale "drug-induced HTN crisis" | documentation | permanent | Prevents future inadvertent NSAID exposure; PCP + pharmacy + family + patient education; medical-alert bracelet for chronic vulnerability (CKD, HF) |
| OTC NSAID counseling — identify hidden sources | Education on OTC ibuprofen, naproxen, aspirin >1 g, combination products (Excedrin, Aleve PM, cold/flu remedies) | education | ongoing | Patients often unaware OTC products contain NSAIDs; pharmacy + caregiver involvement; alternative OTC: acetaminophen for pain, antihistamine for cold without ibuprofen |
Plan: NSAID-induced HTN crisis — STOP NSAID + IV nicardipine + FUROSEMIDE (overcomes renal Na+ retention from prostaglandin loss) + spironolactone if hypoK + IV labetalol adjunct + IV fluids if prerenal AKI + alternative pain regimen (acetaminophen, topical, duloxetine, opioid + multimodal, gabapentinoid, intra-articular steroid) + NSAID-avoid alert + triple-whammy prevention
Contact your care team if any of the following happen:
Call 911 or go to the nearest emergency room right away if you have:
NSAID-AVOIDANCE COUNSELING: comprehensive education on NSAID risks for patient + family + caregivers + PCP + pharmacy team; identify all OTC sources (ibuprofen, naproxen, aspirin >1 g, combination products); MEDICATION-LIST DOCUMENTATION: "NSAID-AVOID" added to allergy list with rationale; ALTERNATIVE PAIN REGIMEN: acetaminophen 1 g PO q6h max 3-4 g/d for general pain (max 2 g/d if cirrhosis), topical NSAID (diclofenac gel, lidocaine patch — minimal systemic) for localized musculoskeletal, duloxetine 30-60 mg PO daily for chronic musculoskeletal, intra-articular steroid for joint-specific, gabapentinoid 100-300 mg TID for neuropathic, opioid for severe acute pain only with multimodal + opioid stewardship; PCP COORDINATION: weekly BP + BMP × 4 weeks then monthly during recovery; KIDNEY RECOVERY: nephrology follow-up in 1-2 weeks for post-AKI surveillance, baseline eGFR re-establishment (some never fully recover after triple-whammy AKI); CV RISK ASSESSMENT: if previously on selective COX-2 for chronic pain, reassess CV risk + consider class avoidance; ALL CARE TEAMS: pharmacy alert on chart "NSAID-AVOID — drug-induced HTN crisis"; PCP + cardiology + nephrology + pain medicine follow-up within 1-2 weeks
Guideline: 2025 ACC/AHA HTN Guideline (Whelton) + KDIGO 2024 CKD/AKI + ACR 2020 Hochberg pain management + Lapi BMJ 2013 (PMID 23299844 triple-whammy AKI cohort)